Carbidopa

Treats symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic…. Sold as Lodosyn. Every FDA application for this active ingredient: 1 branded and 7 generic.

As of Nov 14, 2026, FDA lists 8 applications for Carbidopa (sold as Lodosyn), first approved Apr 25, 1977, with 0 new uses approved and 0 published complete response letters.

First approved: Apr 25, 1977
Applications: 8
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $6.5M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Carbidopa	Part D	$6.5M	-10%	6,512

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

CARBIDOPA 25 MG TABLET: $0.591 per unitGeneric · -16% in a year
CARBIDOPA-LEVO 10-100 MG ODT: $0.598 per unitGeneric · new this year
CARBIDOPA-LEVO 25-100 MG ODT: $0.683 per unitGeneric · -16% in a year
CARBIDOPA-LEVO 25-250 MG ODT: $0.875 per unitGeneric · new this year
CARBIDOPA-LEVO ER 23.75-95 CAP: $3.18 per unitGeneric · new this year
CARBIDOPA-LEVO ER 25-100 TAB: $0.110 per unitGeneric · -8% in a year
CARBIDOPA-LEVO ER 36.25-145 CP: $3.45 per unitGeneric · new this year
CARBIDOPA-LEVO ER 48.75-195 CP: $3.23 per unitGeneric · new this year
CARBIDOPA-LEVO ER 50-200 TAB: $0.178 per unitGeneric · -11% in a year
CARBIDOPA-LEVO ER 61.25-245 CP: $3.95 per unitGeneric · new this year

FDA Drug Safety Communications

One communication since 2020 that name this drug; see all communications

FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/LevodopaMar 20, 2026

Clinical Trials

30 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's PatientsPARKINSON DISEASE (Disorder) · Navamedic AB	Phase 4	Recruiting	Sep 24, 2026
Comparison of Benzhexol and Procyclidine for Tremor in Tremor-Predominant Parkinson's DiseaseParkinson Disease (PD) · safia bano	Not applicable	Recruiting	Sep 9, 2026
Metformin in Parkinson's Disease: Safety and EfficacyParkinsons Disease (PD) · Jinnah Medical & Dental College	Phase 4	Not yet recruiting	Sep 8, 2026
Brain Dopamine BiomarkerParkinson Disease, Healthy Adult Participants · University of South Florida	—	Not yet recruiting	Aug 6, 2026
Sustained Release Oral Formulation For Treatment Of Parkinsons DiseaseHealthy Volunteers · University of Minnesota	Phase 1 / Phase 2	Not yet recruiting	Jul 16, 2026
Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)CTNNB1, L-DOPA · University Hospital, Montpellier	Not applicable	Recruiting	May 29, 2026
Etoricoxib in Patients With Parkinsonian DiseaseParkinson Disease · Ihab Elsayed Hassan	Phase 2	Recruiting	Jan 27, 2026
Celecoxib in Parkinson Disease as Adjuvant TherapyParkinson Disease · Tanta University	Phase 1 / Phase 2	Recruiting	Nov 24, 2025

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Apr 25, 1977	LodosynNDA 17830 · New dosage form	Aton	23	Marketed
Mar 10, 2014	CarbidopaANDA 203261	Ani Pharms	1	Discontinued
Jan 8, 2016	CarbidopaANDA 204291	Alvogen	0	Discontinued
Feb 17, 2016	CarbidopaANDA 205304	Edenbridge Pharms	1	Marketed
Oct 20, 2017	CarbidopaANDA 204763	Novel Labs Inc	0	Marketed
May 7, 2018	CarbidopaANDA 209910	Zydus Pharms	0	Marketed
Oct 21, 2019	CarbidopaANDA 211055	Aurobindo Pharma	0	Marketed
Dec 11, 2023	CarbidopaANDA 217961	Regcon Holdings	0	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA